Fosun Pharma and its partner BioNTech are conducting a coronavirus vaccine trial in China. Photo: Reuters
Coronavirus: Fosun Pharma, BioNTech’s China vaccine trial is an important step before securing marketing approval, companies say
- 144 participants in mainland China will receive two shots of the BNT162b1 coronavirus vaccine candidate spaced by 21 days
- BioNTech among the first international biopharmaceutical companies to start clinical trial of a Covid-19 vaccine candidate in China
Topic |
Coronavirus pandemic
Fosun Pharma and its partner BioNTech are conducting a coronavirus vaccine trial in China. Photo: Reuters